Navigation

CG79 Rheumatoid arthritis: NICE guideline

Corrections

A correction has been made to the guideline. Recommendation 1.4.4.3 has been amended to remove text that stated an incorrect dose of etoricoxib for rheumatoid arthritis patients. The recommendation now reads: When offering treatment with an oral NSAID/COX-2 inhibitor, the first choice should be either a standard NSAID or a COX-2 inhibitor. In either case, these should be co-prescribed with a proton pump inhibitor (PPI), choosing the one with the lowest acquisition cost.

Note that recommendations 1.4.4.2 - 1.4.4.5 are adapted from CG59 Osteoarthritis. These recommendations form part of the rheumatoid arthritis clinical guideline update of the rheumatoid arthritis aspects of TA27 Osteoarthritis and rheumatoid arthritis - cox II inhibitors.

August 2010

In August 2010, NICE published TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor. This replaces TA126 Rheumatoid arthritis (refractory) - rituximab and TA141 Rheumatoid arthritis (refractory) - abatacept, which are referred to in CG79 Rheumatoid arthritis in section 2 of the NICE guideline and in the footnote of page 6 of the quick reference guide. Please see TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor for the updated recommendations.

August 2013

A clarification has been made to recommendation 1.1.1.2 about urgent referral for people with suspected persistent synovitis of undetermined cause.

This page was last updated: 15 August 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.